2011, Number 4
<< Back Next >>
Rev Mex Neuroci 2011; 12 (4)
Hypertrophic Pachymeningitis
Flores SFD, Reyes MIR
Language: Spanish
References: 30
Page: 200-203
PDF size: 342.06 Kb.
ABSTRACT
Hypertrophic pachymeningitis is a disorder of the duramater that causes focal or diffuse thickening. It occurs predominantly in autoimmune, neoplastic and infectious diseases. When the cause is not possible to be established this condition is known as idiopathic hypertrophic pachymeningitis (IHP). Clinically there is involvement of cranial nerves, cerebellar symptoms and paraparesis. The imaging features include isodense (computed tomography scan) or hypointense (magnetic resonance imaging) appearance with great enhancement after the administration of contrast, as well as meningeal thickness exceeding 2 mm. Treatment is focused to correct the cause, and when considering IHP, steroids or low-dose methotrexate could be useful.
REFERENCES
Kuppersmith MJ, Martin V, Heller G, Shah A, Mitnick HJ. Idiopathic hypertrophic pachymeningitis. Neurology 2004; 62: 686-94.
Jimenez PE, Diamantopoulos J, Camacho I. Paquimeningitis hipertrófica craneal y espinal. Descripción de cuatro casos nuevos y revisión de la bibiliografía. Rev Neurol 2006; 43: 470-5.
Hatano N, Behari S, Nagatani T, Kimura M, Ooka K, Saito K, Yoshida J. Idiopathic hypertrophic cranial pachymeningitis: clinicoradiological spectrum and therapeutic options. Neurosurgery 1999; 45: 1336-42.
Riku S, Kato S. Idiopathic hypertrophic pachymeningitis. Neuropathology 2003; 23: 335-44.
Arismendi GJ, Gonzalez M, Molina OM, Cardozo JJ. Paquimeningitis hipertrófica idiopática: un dilema diagnóstico. Rev Neurol. 2004; 39: 830-4.
Iwasaki S, Ito K, Sugasawa M. Hypertrophic cranial pachymeningitis associated with middle ear inflammation. Otol Neurotol 2006; 27: 928-33.
KawanoY, KiraJ. Chronic hypertrophic pachymeningitis associated with HTLV-1 Infection. J Neurol Neurosurg Psychiatry 1995; 59: 435-7.
Nagashima T, Maguchi S, Tereyama Y, Horimoto M, Nemoto M, Nunomura M, Mori M, et al. P-ANCA positive Wegener’s Granulomatosis presenting with hypertrophic pachymeningitis and multiple cranial neuropathies. Neuropathology 2003; 23: 335-44.
Furukawa Y, Matsumoto Y, Yamada M. Hypertrophic pachymeningitis as an initial and cardinal manifestation of microscopic polyangiitis. Neurology. 2004; 63: 1722-4.
Nakamura T, Hirakawa K, Higashi S, et al. CD8+ lymphocites infiltrate predominantly in the inflammatory foci of MPO-ANCA positive thoracic hypertrophic pachymeningitis in a patient with HLA A24. Mod Rheumatol 2007; 17: 75-80.
Blaser S, Salzman KL. Hypertrophic pachymeningitis. 1st. Ed. In: Osborn Diagnostic Imaging Brain. Canada: AMIRSYS; 2004, p. II.4.30-32.
Sylaja PN, Cherian PJ, Das CK, Radhakrishnan VV, Radhakrishnan K. Idiopathic hypertrophic cranial pachymeningitis. Neurol India 2002; 50: 53-9.
Ruiz-Sandoval JL, Bernard-Medina G, Ramos-Gómez EJ, Romero- Vargas S, Gutiérrez-Ureña S, González-Cornejo S, Chiquete E. Idiopathic hypertrophic cranial pachymeningitis successfully treated with weekly subcutaneous methotrexate. Acta Neurochir (Wien) 2006; 148: 1011-4.
Bosman T, Simonin C, Launay D, Caron S, Destée A, Defebvre L. Idiopathic hypertrophic cranial pachymeningitis treated by oral methotrexate: a case report and review of literature. Rheumatol Int 2008; 28: 713-8.
van Toorn R, Esser M, Smit D, Andronikou S. Idiopathic hypertrophic cranial pachymeningitis causing progressive polyneuropathies in a child. Eur J Paediatr Neurol 2008; 12: 144-7.
Kuppersmith MJ, Martin V, Heller G, Shah A, Mitnick HJ. Idiopathic hypertrophic pachymeningitis. Neurology 2004; 62: 686-94.
Jimenez PE, Diamantopoulos J, Camacho I. Paquimeningitis hipertrófica craneal y espinal. Descripción de cuatro casos nuevos y revisión de la bibiliografía. Rev Neurol 2006; 43: 470-5.
Hatano N, Behari S, Nagatani T, Kimura M, Ooka K, Saito K, Yoshida J. Idiopathic hypertrophic cranial pachymeningitis: clinicoradiological spectrum and therapeutic options. Neurosurgery 1999; 45: 1336-42.
Riku S, Kato S. Idiopathic hypertrophic pachymeningitis. Neuropathology 2003; 23: 335-44.
Arismendi GJ, Gonzalez M, Molina OM, Cardozo JJ. Paquimeningitis hipertrófica idiopática: un dilema diagnóstico. Rev Neurol. 2004; 39: 830-4.
Iwasaki S, Ito K, Sugasawa M. Hypertrophic cranial pachymeningitis associated with middle ear inflammation. Otol Neurotol 2006; 27: 928-33.
KawanoY, KiraJ. Chronic hypertrophic pachymeningitis associated with HTLV-1 Infection. J Neurol Neurosurg Psychiatry 1995; 59: 435-7.
Nagashima T, Maguchi S, Tereyama Y, Horimoto M, Nemoto M, Nunomura M, Mori M, et al. P-ANCA positive Wegener’s Granulomatosis presenting with hypertrophic pachymeningitis and multiple cranial neuropathies. Neuropathology 2003; 23: 335-44.
Furukawa Y, Matsumoto Y, Yamada M. Hypertrophic pachymeningitis as an initial and cardinal manifestation of microscopic polyangiitis. Neurology. 2004; 63: 1722-4.
Nakamura T, Hirakawa K, Higashi S, et al. CD8+ lymphocites infiltrate predominantly in the inflammatory foci of MPO-ANCA positive thoracic hypertrophic pachymeningitis in a patient with HLA A24. Mod Rheumatol 2007; 17: 75-80.
Blaser S, Salzman KL. Hypertrophic pachymeningitis. 1st. Ed. In: Osborn Diagnostic Imaging Brain. Canada: AMIRSYS; 2004, p. II.4.30-32.
Sylaja PN, Cherian PJ, Das CK, Radhakrishnan VV, Radhakrishnan K. Idiopathic hypertrophic cranial pachymeningitis. Neurol India 2002; 50: 53-9.
Ruiz-Sandoval JL, Bernard-Medina G, Ramos-Gómez EJ, Romero- Vargas S, Gutiérrez-Ureña S, González-Cornejo S, Chiquete E. Idiopathic hypertrophic cranial pachymeningitis successfully treated with weekly subcutaneous methotrexate. Acta Neurochir (Wien) 2006; 148: 1011-4.
Bosman T, Simonin C, Launay D, Caron S, Destée A, Defebvre L. Idiopathic hypertrophic cranial pachymeningitis treated by oral methotrexate: a case report and review of literature. Rheumatol Int 2008; 28: 713-8.
van Toorn R, Esser M, Smit D, Andronikou S. Idiopathic hypertrophic cranial pachymeningitis causing progressive polyneuropathies in a child. Eur J Paediatr Neurol 2008; 12: 144-7.